Tag Levi Garraway

The European Commission has granted marketing authorisation for Tecentriq® SC, the EU’s first PD-(L)1 cancer immunotherapy for subcutaneous injection. 

The European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union’s first PD-(L)1 cancer immunotherapy for subcutaneous injection.  Roche announced that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union’s first PD-(L)1…

The primary analysis of the Phase 3 HAVEN 7 study reinforced the efficacy and safety of Hemlibra® in previously untreated or minimally treated infants with severe haemophilia A without Factor VIII inhibitors.

Roche announced that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® (emicizumab) in previously untreated or minimally treated infants with severe haemophilia A without factor VIII inhibitors. Results showed that Hemlibra…

Positive long-term follow-up data from the pivotal, Phase 3 KATHERINE study in people with HER2-positive early-stage breast cancer who have residual invasive disease following neoadjuvant treatment.

Roche announced positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (eBC) who have residual invasive disease following neoadjuvant (before surgery) treatment. “We are pleased that Kadcyla could offer people with…

Positive results from the Phase 3 INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, HR-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.

Genentech, a member of the Roche Group, announced positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance®) and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, hormone receptor…